Laigo Bio
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.
Laigo Bio has raised $6.4M across 1 round. Its most recent round was a Seed of $6.4M in Mar 2026. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Laigo Bio is featured in
Similar companies
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise has created the base for the Trammpolin design and the development towards a prototype.
Detact holds the patent for a new, innovative, real-time, bacterial detection system that enables hospital staff to determine bacterial presence on surface areas with an easy to use system: the b-Swab.
Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs.
Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based malignant growth tests to analyze a scope of diseases precisely. The tests depend on the study of Nucleosomics, which is the act of distinguishing and estimating nucleosomes in the circulation system or other natural liquid which means that illness is available. As disease screening programs become an ever increasing number of far and wide, its items mean to assist with diagnosing a scope of tumors rapidly, basically, precisely, and cost-really. Early analysis can possibly draw out the existence of patients as well as to work on their personal satisfaction. Volition's innovative work exercises are right now focused in Belgium, with extra workplaces in London, Texas, and Singapore, as the organization centers around putting up its demonstrative items for sale to the public first in Europe, then, at that point, in the U.S. furthermore, around the world.
PhenoTips is a computer software company that provides solution for clinical genetics, phenotyping, and human phenotype ontology. It offers smart software solutions streamlined for clinical use that can be integrated with existing electronic health records. The company was founded in 2014 and headquartered in Ontario, Canada.
Ammortal is a healthcare services company that offers bio-optimization services.
Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.
Swaza develops nanotechnology-based therapeutics designed to address critical medical conditions involving impaired oxygen delivery and tissue healing. The company focuses on a nanofluid breathing aid, AeroHeal, which delivers oxygen and removes carbon dioxide in patients with compromised lungs, eliminating the need for invasive ventilation. Their primary product, SWAZA-1, is a non-invasive nanofluid that facilitates gas exchange in damaged lungs. Additionally, SWAZA-2 is an oxygen-enriched biomaterial aimed at enhancing wound healing, and SWAZA-3 is a thermoreversible enema intended for emergency oxygenation.
A cell therapy business called Immusoft is dedicated to creating revolutionary treatments for uncommon diseases by leveraging sustained delivery of therapeutic proteins from a patient's own cells. Immune System Programming (ISPTM), a technology platform being developed by the company, alters a patient's B cells and teaches them to create gene-encoded medications. The ISP-reprogrammed B cells develop into tiny drug factories that are anticipated to live in patients for many years and give therapeutic effect. The business is based in Seattle, Washington.
Defeat the mutants.
At Pegasus Biotech, our goal is to collaborate with clients to introduce innovative advancements to the global human and animal health sectors. We specialize in guaranteeing that the development processes for client projects, whether in the early stages or transitioning to production, lead to successful products that meet global regulatory standards.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.